Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Soft Tissue Neoplasms | 16 | 2024 | 1165 | 3.650 |
Why?
|
Sarcoma | 8 | 2024 | 1802 | 1.990 |
Why?
|
Vascular Malformations | 6 | 2021 | 471 | 1.450 |
Why?
|
Fibrosarcoma | 5 | 2024 | 313 | 1.320 |
Why?
|
Lipoma | 2 | 2023 | 294 | 1.260 |
Why?
|
Myofibromatosis | 2 | 2023 | 28 | 1.030 |
Why?
|
Hemangioma | 4 | 2023 | 723 | 0.970 |
Why?
|
Sarcoma, Clear Cell | 2 | 2022 | 75 | 0.910 |
Why?
|
Bone Neoplasms | 8 | 2024 | 2567 | 0.860 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2023 | 103 | 0.820 |
Why?
|
Myxoma | 1 | 2023 | 115 | 0.810 |
Why?
|
Fibromatosis, Aggressive | 1 | 2023 | 125 | 0.790 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2023 | 220 | 0.750 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.740 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2021 | 43 | 0.740 |
Why?
|
Sarcoma, Synovial | 2 | 2020 | 155 | 0.710 |
Why?
|
Tandem Repeat Sequences | 1 | 2021 | 184 | 0.700 |
Why?
|
Child | 55 | 2024 | 80564 | 0.680 |
Why?
|
Hemangioendothelioma, Epithelioid | 4 | 2023 | 52 | 0.660 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2023 | 2423 | 0.660 |
Why?
|
Neoplasms, Adipose Tissue | 1 | 2019 | 12 | 0.640 |
Why?
|
Vascular Neoplasms | 1 | 2020 | 167 | 0.630 |
Why?
|
Giant Cell Tumor of Bone | 2 | 2018 | 119 | 0.630 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2018 | 33 | 0.620 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2024 | 1608 | 0.610 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2023 | 1624 | 0.610 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 228 | 0.600 |
Why?
|
Neoplasms, Muscle Tissue | 3 | 2024 | 69 | 0.580 |
Why?
|
Hamartoma | 2 | 2017 | 233 | 0.570 |
Why?
|
Neoplasms, Connective and Soft Tissue | 3 | 2023 | 34 | 0.550 |
Why?
|
Fibroma | 1 | 2018 | 197 | 0.540 |
Why?
|
Proto-Oncogene Proteins | 4 | 2022 | 4520 | 0.530 |
Why?
|
Neck | 1 | 2021 | 733 | 0.520 |
Why?
|
Child, Preschool | 33 | 2024 | 42500 | 0.510 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2024 | 3655 | 0.510 |
Why?
|
Gene Rearrangement | 5 | 2024 | 1144 | 0.500 |
Why?
|
Infant | 26 | 2024 | 36386 | 0.490 |
Why?
|
Head | 1 | 2021 | 925 | 0.480 |
Why?
|
Arteriovenous Malformations | 4 | 2020 | 397 | 0.440 |
Why?
|
Specimen Handling | 2 | 2020 | 704 | 0.430 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2034 | 0.430 |
Why?
|
Poly(A)-Binding Proteins | 1 | 2013 | 35 | 0.420 |
Why?
|
Mutation | 13 | 2024 | 30198 | 0.400 |
Why?
|
Pathology, Clinical | 1 | 2016 | 377 | 0.400 |
Why?
|
Neurofibrosarcoma | 2 | 2023 | 28 | 0.380 |
Why?
|
Receptor, trkA | 3 | 2023 | 159 | 0.380 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2921 | 0.370 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2013 | 125 | 0.370 |
Why?
|
Bone Marrow Diseases | 1 | 2013 | 234 | 0.370 |
Why?
|
Repressor Proteins | 2 | 2021 | 2968 | 0.370 |
Why?
|
Hemangiosarcoma | 2 | 2023 | 211 | 0.360 |
Why?
|
RNA-Binding Protein EWS | 2 | 2024 | 212 | 0.340 |
Why?
|
Adolescent | 34 | 2024 | 88835 | 0.330 |
Why?
|
Carcinoma | 1 | 2021 | 2312 | 0.330 |
Why?
|
Biopsy, Fine-Needle | 2 | 2022 | 1133 | 0.330 |
Why?
|
Subcutaneous Tissue | 2 | 2021 | 130 | 0.330 |
Why?
|
Female | 61 | 2024 | 396112 | 0.310 |
Why?
|
Male | 49 | 2024 | 363698 | 0.300 |
Why?
|
Humans | 85 | 2024 | 765968 | 0.300 |
Why?
|
Liver Neoplasms | 2 | 2021 | 4353 | 0.300 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2020 | 330 | 0.290 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4274 | 0.290 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2020 | 1761 | 0.290 |
Why?
|
Fasciitis | 2 | 2019 | 68 | 0.280 |
Why?
|
Immunohistochemistry | 9 | 2024 | 11022 | 0.270 |
Why?
|
Neurofibromatosis 1 | 2 | 2023 | 560 | 0.260 |
Why?
|
Infant, Newborn | 11 | 2024 | 26346 | 0.260 |
Why?
|
Bone Marrow Cells | 1 | 2013 | 2412 | 0.250 |
Why?
|
Neoplasms, Second Primary | 1 | 2013 | 1050 | 0.240 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2019 | 456 | 0.230 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2024 | 44 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9373 | 0.230 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2024 | 2505 | 0.220 |
Why?
|
Nevus, Blue | 1 | 2024 | 45 | 0.220 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2024 | 77 | 0.220 |
Why?
|
Oncogene Fusion | 2 | 2021 | 84 | 0.210 |
Why?
|
Brain Neoplasms | 2 | 2022 | 9071 | 0.210 |
Why?
|
Diagnosis, Differential | 8 | 2024 | 12976 | 0.210 |
Why?
|
Referral and Consultation | 1 | 2016 | 3615 | 0.210 |
Why?
|
Bone Marrow | 1 | 2013 | 2921 | 0.210 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2022 | 40 | 0.210 |
Why?
|
Myofibroblasts | 1 | 2024 | 229 | 0.210 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 2 | 2023 | 182 | 0.200 |
Why?
|
Neoplasm Proteins | 2 | 2024 | 3596 | 0.200 |
Why?
|
Skin Neoplasms | 3 | 2024 | 5849 | 0.200 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2023 | 182 | 0.200 |
Why?
|
Dyskeratosis Congenita | 1 | 2023 | 70 | 0.200 |
Why?
|
Nose Neoplasms | 2 | 2015 | 249 | 0.190 |
Why?
|
Nephroma, Mesoblastic | 1 | 2022 | 25 | 0.190 |
Why?
|
Endodermal Sinus Tumor | 1 | 2022 | 52 | 0.190 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2021 | 36 | 0.190 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 323 | 0.190 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2023 | 170 | 0.190 |
Why?
|
Hemangioendothelioma | 1 | 2022 | 112 | 0.190 |
Why?
|
Necrosis | 2 | 2023 | 1617 | 0.190 |
Why?
|
Diarrhea, Infantile | 1 | 2021 | 100 | 0.180 |
Why?
|
Receptor, TIE-2 | 1 | 2021 | 183 | 0.180 |
Why?
|
Lip | 1 | 2022 | 195 | 0.180 |
Why?
|
Hypertension, Portal | 1 | 2023 | 229 | 0.180 |
Why?
|
Malabsorption Syndromes | 1 | 2021 | 135 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 4405 | 0.170 |
Why?
|
Granuloma, Pyogenic | 1 | 2020 | 47 | 0.170 |
Why?
|
Homeodomain Proteins | 3 | 2024 | 2428 | 0.170 |
Why?
|
Endothelial Cells | 3 | 2022 | 3584 | 0.170 |
Why?
|
Disorders of Sex Development | 1 | 2021 | 129 | 0.170 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 904 | 0.160 |
Why?
|
Codon | 1 | 2021 | 595 | 0.160 |
Why?
|
Myofibroma | 1 | 2019 | 45 | 0.160 |
Why?
|
Teratoma | 1 | 2022 | 401 | 0.160 |
Why?
|
Prognosis | 9 | 2020 | 29922 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 4642 | 0.160 |
Why?
|
Oncogenes | 2 | 2022 | 1235 | 0.160 |
Why?
|
Genital Neoplasms, Female | 1 | 2024 | 533 | 0.160 |
Why?
|
Osteosarcoma | 1 | 2024 | 909 | 0.150 |
Why?
|
Sarcoma, Kaposi | 1 | 2022 | 375 | 0.150 |
Why?
|
Metabolism, Inborn Errors | 1 | 2021 | 291 | 0.150 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 190 | 0.150 |
Why?
|
Eye Abnormalities | 1 | 2021 | 243 | 0.150 |
Why?
|
Cartilage Diseases | 1 | 2020 | 159 | 0.150 |
Why?
|
beta Catenin | 1 | 2023 | 1043 | 0.150 |
Why?
|
WT1 Proteins | 1 | 2018 | 182 | 0.150 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 2018 | 186 | 0.150 |
Why?
|
Salivary Gland Neoplasms | 1 | 2022 | 305 | 0.150 |
Why?
|
Parotid Neoplasms | 1 | 2019 | 157 | 0.150 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2023 | 730 | 0.140 |
Why?
|
Stem Cell Niche | 1 | 2021 | 346 | 0.140 |
Why?
|
Solitary Fibrous Tumors | 1 | 2018 | 70 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 480 | 0.140 |
Why?
|
Lymphatic Diseases | 1 | 2018 | 317 | 0.140 |
Why?
|
Liposarcoma | 1 | 2019 | 288 | 0.140 |
Why?
|
Scalp | 1 | 2019 | 388 | 0.130 |
Why?
|
Wnt Proteins | 1 | 2021 | 722 | 0.130 |
Why?
|
Atrial Septum | 1 | 2017 | 61 | 0.130 |
Why?
|
Adipocytes | 1 | 2023 | 1194 | 0.130 |
Why?
|
Reoperation | 2 | 2024 | 4294 | 0.130 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2017 | 116 | 0.130 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 961 | 0.130 |
Why?
|
Young Adult | 16 | 2024 | 59889 | 0.130 |
Why?
|
Adult | 22 | 2024 | 223044 | 0.130 |
Why?
|
Appendix | 1 | 2017 | 109 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2017 | 254 | 0.130 |
Why?
|
Leg Injuries | 1 | 2017 | 179 | 0.120 |
Why?
|
Muscular Diseases | 1 | 2020 | 550 | 0.120 |
Why?
|
Congenital Abnormalities | 1 | 2020 | 704 | 0.120 |
Why?
|
Exons | 1 | 2021 | 2391 | 0.120 |
Why?
|
GTP Phosphohydrolases | 1 | 2018 | 523 | 0.120 |
Why?
|
Skull | 1 | 2019 | 811 | 0.120 |
Why?
|
Endemic Diseases | 1 | 2016 | 189 | 0.120 |
Why?
|
Rhabdomyosarcoma | 1 | 2018 | 354 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2022 | 976 | 0.120 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2016 | 327 | 0.110 |
Why?
|
Diarrhea | 1 | 2021 | 1316 | 0.110 |
Why?
|
Upper Extremity | 1 | 2019 | 682 | 0.110 |
Why?
|
Glycoproteins | 1 | 2021 | 2195 | 0.110 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2017 | 328 | 0.100 |
Why?
|
Meningioma | 1 | 2021 | 1221 | 0.100 |
Why?
|
Liver Diseases | 1 | 2021 | 1303 | 0.100 |
Why?
|
Neoplasms | 4 | 2024 | 22340 | 0.100 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 1252 | 0.100 |
Why?
|
Chordoma | 1 | 2015 | 343 | 0.100 |
Why?
|
Liver Transplantation | 1 | 2024 | 2412 | 0.100 |
Why?
|
Neurilemmoma | 1 | 2017 | 522 | 0.100 |
Why?
|
Lower Extremity | 1 | 2020 | 1226 | 0.100 |
Why?
|
Skin Diseases | 1 | 2020 | 1088 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1119 | 0.090 |
Why?
|
Hypoplastic Left Heart Syndrome | 1 | 2017 | 595 | 0.090 |
Why?
|
Biopsy | 5 | 2024 | 6763 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2021 | 2054 | 0.090 |
Why?
|
Lung | 2 | 2022 | 10033 | 0.090 |
Why?
|
Pancreatitis | 1 | 2018 | 1087 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2016 | 398 | 0.090 |
Why?
|
Histones | 2 | 2023 | 2584 | 0.090 |
Why?
|
Osteochondroma | 1 | 2011 | 44 | 0.090 |
Why?
|
Cytogenetic Analysis | 1 | 2011 | 269 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6499 | 0.080 |
Why?
|
Genomics | 5 | 2024 | 5929 | 0.080 |
Why?
|
Fatty Liver | 1 | 2016 | 807 | 0.080 |
Why?
|
DNA Methylation | 2 | 2023 | 4424 | 0.080 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2011 | 416 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2022 | 5696 | 0.080 |
Why?
|
Ultrasonography, Prenatal | 1 | 2017 | 1774 | 0.080 |
Why?
|
Cell Proliferation | 1 | 2024 | 10429 | 0.080 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2011 | 640 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39193 | 0.070 |
Why?
|
Malaria, Falciparum | 1 | 2016 | 1075 | 0.070 |
Why?
|
Molecular Biology | 2 | 2022 | 574 | 0.070 |
Why?
|
Retrospective Studies | 10 | 2024 | 81514 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3493 | 0.070 |
Why?
|
Molecular Targeted Therapy | 3 | 2024 | 2822 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 5995 | 0.070 |
Why?
|
Syndrome | 2 | 2024 | 3271 | 0.070 |
Why?
|
Plasmodium falciparum | 1 | 2016 | 1738 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4900 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 1 | 2015 | 1404 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2011 | 1394 | 0.060 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 4958 | 0.060 |
Why?
|
Pain | 1 | 2020 | 5077 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10603 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2942 | 0.060 |
Why?
|
Liver | 2 | 2021 | 7562 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3458 | 0.060 |
Why?
|
Middle Aged | 10 | 2024 | 223009 | 0.060 |
Why?
|
Pancreatic Neoplasms | 2 | 2021 | 5444 | 0.060 |
Why?
|
Endothelium, Lymphatic | 1 | 2024 | 63 | 0.060 |
Why?
|
Epithelioid Cells | 1 | 2024 | 60 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5719 | 0.060 |
Why?
|
Primary Graft Dysfunction | 1 | 2024 | 112 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20124 | 0.050 |
Why?
|
Angiomyolipoma | 1 | 2024 | 190 | 0.050 |
Why?
|
Leukoplakia, Oral | 1 | 2023 | 79 | 0.050 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2024 | 207 | 0.050 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.050 |
Why?
|
S100 Proteins | 1 | 2022 | 217 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12509 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2023 | 260 | 0.050 |
Why?
|
Postoperative Complications | 1 | 2024 | 15747 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2018 | 7851 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2022 | 169 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2021 | 6069 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2024 | 691 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 561 | 0.040 |
Why?
|
Salivary Glands | 1 | 2022 | 231 | 0.040 |
Why?
|
Base Sequence | 2 | 2022 | 12403 | 0.040 |
Why?
|
Genitalia | 1 | 2021 | 114 | 0.040 |
Why?
|
Gene Fusion | 1 | 2023 | 357 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8611 | 0.040 |
Why?
|
Public Opinion | 1 | 2024 | 482 | 0.040 |
Why?
|
Tissue Banks | 1 | 2020 | 183 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 647 | 0.040 |
Why?
|
Phenotype | 3 | 2021 | 16721 | 0.040 |
Why?
|
Dissection | 1 | 2020 | 299 | 0.040 |
Why?
|
Sclerotherapy | 1 | 2019 | 184 | 0.040 |
Why?
|
STAT6 Transcription Factor | 1 | 2018 | 197 | 0.040 |
Why?
|
Gastric Mucosa | 1 | 2021 | 602 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2022 | 1066 | 0.040 |
Why?
|
Aged | 6 | 2021 | 171117 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11888 | 0.030 |
Why?
|
Tongue | 1 | 2020 | 405 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6832 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13451 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8529 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 735 | 0.030 |
Why?
|
Rare Diseases | 1 | 2021 | 635 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2018 | 656 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3608 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 41649 | 0.030 |
Why?
|
Point Mutation | 1 | 2021 | 1590 | 0.030 |
Why?
|
Reticulin | 1 | 2015 | 19 | 0.030 |
Why?
|
Recurrence | 2 | 2020 | 8501 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23601 | 0.030 |
Why?
|
Fetal Heart | 1 | 2017 | 281 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2016 | 476 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3202 | 0.030 |
Why?
|
North America | 1 | 2018 | 1285 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2024 | 2880 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2024 | 15398 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2631 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2796 | 0.030 |
Why?
|
Ultrasonography | 2 | 2017 | 5993 | 0.030 |
Why?
|
Fetus | 1 | 2021 | 1870 | 0.030 |
Why?
|
Graft Survival | 1 | 2024 | 3890 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12795 | 0.030 |
Why?
|
Transcription Factors | 2 | 2024 | 12131 | 0.030 |
Why?
|
Mitosis | 1 | 2018 | 1173 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2132 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20659 | 0.020 |
Why?
|
Accidents, Traffic | 1 | 2017 | 818 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2021 | 2589 | 0.020 |
Why?
|
Graft Rejection | 1 | 2024 | 4499 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2019 | 3737 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2045 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6897 | 0.020 |
Why?
|
Ulna | 1 | 2011 | 133 | 0.020 |
Why?
|
Collagen | 1 | 2018 | 2618 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2021 | 3046 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5783 | 0.020 |
Why?
|
Boston | 1 | 2022 | 9338 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8041 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2020 | 65188 | 0.020 |
Why?
|
Fibrosis | 1 | 2015 | 2070 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3559 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17075 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4893 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 36532 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3910 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2226 | 0.020 |
Why?
|
Genetic Variation | 1 | 2018 | 6610 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11206 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2018 | 59489 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13632 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2019 | 11641 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10850 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12768 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18380 | 0.010 |
Why?
|
Animals | 2 | 2024 | 168764 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14652 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18071 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 54802 | 0.010 |
Why?
|
Mice | 1 | 2024 | 81819 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 30260 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26318 | 0.010 |
Why?
|